Immunszintigraphie xenotrans-plantierter Mammakarzinome

Zusammenfassung

Gegenstand dieser Arbeit waren tierexperimentelle Untersuchungen zur Biodistribution und Immunszintigraphie der Anti-Muzin-MoAbs 12H12 und BM-7 in thymusaplastischen Nacktmäusen mit xenotransplantierten humanen Mammakarzinomen. Die MoAb waren mit ^99mTc markiert; ihre Biodistribution wurde im Tiermodell 24 und 48 h nach i. v. Injektion untersucht. Die ^99mTc-Markierungen der MoAbs 12H12 und BM-7 führten zu einer Tumoranreicherung von 20,7% bzw. 8,8% ID/g und zu Tumor/Muskel-Quotienten von 31 bzw. 18 nach 48 h. Im-munszintigraphisch ließ sich mit beiden MoAbs nach 24 h das Mammakarzinom AR gut darstellen. Die beiden MoAbs erfahren im Tiermodell eine schnelle Tumoraufnahme und rasche Blut-Clearance.

Summary

The present study was undertaken to evaluate the correlation of the favorable in vitro characteristics of the anti-mucin Mabs 12H12 and BM-7 with high tumor accumulation in vivo. They were labeled with ^99mTc; their biodistribution in nude mice bearing mammary tumor xenograft AR was examined and immunoscintigraphy was performed after 24 h. ^99mTc-labeling of the Mabs 12H12 and BM-7 led to tumor uptakes of 20.7% and 8.8% ID/g, respectively, after 48 h. Tumor-to-muscle ratios were 31 (12H12) and 18 (BM-7). Tumor xenografts were clearly visualized in immunoscintigrams. Combination of Mab 12H12 and ^99mTc provides high tumor-to-tissue ratios shortly after administration.

Schlüsselwörter

Immunszintigraphie - Muzin - MUC1 - Mammakarzinom - ^99mTc - 12H12 - BM-7

Keywords

Immunoscintigraphy - mucin - MUC1 - breast cancer - ^99mTc - 12H12 - BM-7

• LITERATUR

• 1 Athanassiou A, Pectasides D, Pateniotis K. et al. Immunoscintigraphy with ¹³¹I-labeled HMFG-2 and HMFG-1 F(ab’)₂ in the preoperative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer 1988; 3 Suppl 89-95.
• 2 Bastert G, Eichler A, Kaul S. Monoclonal antibodies against human breast cancer. In: Immune-deficient animals in biomedical research. Rygaard Brünner. (eds). Basel: Karger; 1987: 224-7.
• 3 Baum RP, Hertel A, Lorenz M. et al. ^99mTc labeled anti-CEA monoclonal antibody for tumor immunoscintigraphy: first clinical results. Nucl Med Commun 1989; 10: 345-52.
• 4 Briimmendorf TH, Kaul S, Schuhmacher J. et al. Immunoscintigraphy of human mammary carcinoma xenografts using monoclonal antibodies 12H12 and BM-2 labeled with ^99mTc and radioiodine. Cancer Res 1994; 54: 4162-8.
• 5 DeLand FH, Kim E, Corgan R. et al. Axillary lymphoscintigraphy in radioimmunodetec-tion of carcinoembryonic antigen in breast cancer. J Nucl Med 1979; 20: 1243-50.
• 6 Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820-2.
• 6a Hnatovich DJ, Mardirossian G, Rusckowski M. et al. Directly and indirectly ^99mTc-labeled antibodies. A comparison of in vitro and animal in vivo properties. J Nucl Med 1993; 34: 109-19.
• 7 Kairemo KJ. Immunolymphoscintigraphy with ^99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Res 1990; 50 Suppl 449-54.
• 8 Kaul S, Windecker S, Bastert G. Monoclonal antibodies reactive with tumor-associated epitopes of breast mucin glycoproteins. Proc Am Assoc Cancer Res 1989; 30: 349.
• 9 Kaul S, Bastert G. Monoklonale Antikörper zur Diagnostik und Therapie bei gynäkologischen Tumoren einschließlich des Mammakarzinoms. Aktuelle Onkologie 42. München: Zuckerschwert; 1987: 42.
• 9a Kaul S, Windecker S, Bastert G. TAG12: Reinigung und Produktion von monoklonalen Zweitantikörpern. Aktuelle Onkologie 50. München: Zuckerschwert; 1989: 47-53.
• 10 Lamki LM, Buzdar AU, Singletary E. et al. Indium-Ill labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase 1 study. J Nucl Med 1991; 32: 1326-32.
• 11 Lightenberg MJL, Genissen AMC, Vos HL, Hilkens J. A single nucleotide polymorphism in an exon dictates allele-dependent differential splicing of episilian mRNA. Nucleic Acids Res 1990; 19: 297-301.
• 12 Lind P, Smola MG, Lechner P. et al. The immunoscintigraphic use of ^99mTc-labeled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991; 47: 865-9.
• 13 Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immuno-reactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984; 72: 77-89.
• 14 Mardirossian G, Wu C, Rusckowski M, Hnatovich DJ. The stability of ^99mTc directly labeled to an Fab’ antibody via stannous ion and mercaptoethanol reduction. Nucl Med Commun 1992; 13: 503-12.
• 15 Mattes MJ, Major PP, Goldenberg DM. et al. Pattern of antigen distribution in human carcinomas. Cancer Res 1990; 50 Suppl 880-4.
• 16 Matzku S, Bihl H. Tumor localization by immunoscintigraphy: potential and limitations. In: Molecular diagnosis of cancer. Wagener Neumann. (eds). Berlin, Heidelberg, New York: Springer; 1993: 207-17.
• 17 Merino MJ, Monteagudo C, Neumann RD. Monoclonal antibodies for radioimmuno-scintigraphy of breast cancer, Vol 18. Nucl Med Biol 1991; 4: 437-43.
• 18 Pateisky N, Schatten C, Enzelsberger H. et al. Immunlymphszintigraphie. Dtsch Med Wschr 1988; 113: 250-5.
• 19 Robbins PF, Eggensperger D, Qi C-F, Schlom J. Definition of the expression of the human carcinoembryonic antigen and nonspecific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993; 53: 892-7.
• 20 Salgado L, Vieira MR, Baum RP. et al. Clinical value of immunoscintigraphy in breast cancer patients with a new antibody (12H12) labeled with ^99mTc. Book of abstracts, 5th annual meeting on diagnostic and therapeutic applications of radiolabeled antibodies and receptors for diagnostic and therapeutic purposes, Ft. Lauderdale, Jan. 14th—17th, 1993
• 21 Schlom J. Basic principles and application of monoclonal antibodies in the management of carcinomas. Cancer Res 1986; 46: 3225-38.
• 22 Schuhmacher J, Klivényi G, Matys R. et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995; 55: 115-23.
• 23 Schwarz A, Steinsträsser A. A novel approach to ^99mTc labeled monoclonal antibodies (abstract). J Nucl Med 1987; 28: 721.
• 24 Strous GJ, Dekker J. Mucin-type glycoproteins. Critic Rev Biochem Mol Biol 1992; 27: 57-92.
• 25 Swallow DM, Gendler S, Griffith B. et al. The human tumor-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987; 328: 82.
• 26 Sykes TR, Woo TK, Qi P, Baum RP, Noujaim AA. Direct labeling with ^99mTc by a novel photoactivation process. J Nucl Med 1993; 35 Suppl 100.
• 27 Taylor-Papadimitriou J, Peterson JA, Arklie J. et al. Monoclonal antibodies to epithelial-specific components of the human milk fat globule membrane. Production and reaction with cells in the culture. Int J Cancer 1981; 2: 17-28.
• 28 Windecker S, Khazaeli MB, LoBulgio AF, Shaw DR, Kaul S. Circulating level of TAG-12 breast carcinoma-associated antigen. Proc Am Assoc Cancer Res 1990; 31: 262.
• 29 Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988; 11: 55-101.